These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26019274)

  • 21. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.
    Varypataki EM; van der Maaden K; Bouwstra J; Ossendorp F; Jiskoot W
    AAPS J; 2015 Jan; 17(1):216-26. PubMed ID: 25387996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.
    Varypataki EM; Hasler F; Waeckerle-Men Y; Vogel-Kindgen S; Høgset A; Kündig TM; Gander B; Halin C; Johansen P
    Front Immunol; 2019; 10():1548. PubMed ID: 31333674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.
    Shen H; Ackerman AL; Cody V; Giodini A; Hinson ER; Cresswell P; Edelson RL; Saltzman WM; Hanlon DJ
    Immunology; 2006 Jan; 117(1):78-88. PubMed ID: 16423043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
    San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
    Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recruitment of bone marrow CD11b
    Yang YW; Luo WH
    Sci Rep; 2017 Mar; 7():44691. PubMed ID: 28317931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system.
    Yamaoka A; Guan X; Takemoto S; Nishikawa M; Takakura Y
    J Control Release; 2010 Mar; 142(3):411-5. PubMed ID: 19913062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.
    Zhang Z; Tongchusak S; Mizukami Y; Kang YJ; Ioji T; Touma M; Reinhold B; Keskin DB; Reinherz EL; Sasada T
    Biomaterials; 2011 May; 32(14):3666-78. PubMed ID: 21345488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins.
    Breloer M; Fleischer B; von Bonin A
    J Immunol; 1999 Mar; 162(6):3141-7. PubMed ID: 10092763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice.
    Mohanan D; Gander B; Kündig TM; Johansen P
    Eur J Pharm Biopharm; 2012 Feb; 80(2):274-81. PubMed ID: 22024408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced generation of cytotoxic T lymphocytes by increased cytosolic delivery of MHC class I epitope fused to mouse heat shock protein 70 via polyhistidine conjugation.
    Takemoto S; Nishikawa M; Otsuki T; Yamaoka A; Maeda K; Ota A; Takakura Y
    J Control Release; 2009 Apr; 135(1):11-8. PubMed ID: 19100299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice.
    Li J; Li W; Liang S; Cai D; Kieny MP; Jacob L; Linnenbach A; Abramczuk JW; Bender H; Sproesser K; Swoboda R; Somasundaram R; Guerry D; Herlyn D
    J Immunol; 2003 Sep; 171(6):2922-9. PubMed ID: 12960315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses.
    Terhorst D; Fossum E; Baranska A; Tamoutounour S; Malosse C; Garbani M; Braun R; Lechat E; Crameri R; Bogen B; Henri S; Malissen B
    J Immunol; 2015 Jun; 194(12):5895-902. PubMed ID: 25941327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.